1,128,584 Shares in Allogene Therapeutics Inc (ALLO) Acquired by venBio Select Advisor LLC

Share on StockTwits

venBio Select Advisor LLC acquired a new stake in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,128,584 shares of the company’s stock, valued at approximately $27,753,000. Allogene Therapeutics makes up about 1.7% of venBio Select Advisor LLC’s portfolio, making the stock its 14th biggest position. venBio Select Advisor LLC owned approximately 0.93% of Allogene Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Sphera Funds Management LTD. acquired a new stake in shares of Allogene Therapeutics in the 4th quarter valued at $3,055,000. Lord Abbett & CO. LLC bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $10,826,000. American International Group Inc. bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $379,000. Geode Capital Management LLC bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $8,592,000. Finally, Northern Trust Corp bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $7,709,000. 44.94% of the stock is currently owned by hedge funds and other institutional investors.

ALLO has been the subject of a number of research analyst reports. Cowen reaffirmed a “buy” rating on shares of Allogene Therapeutics in a report on Friday, March 8th. Zacks Investment Research cut Allogene Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 28th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $29.00 price target on shares of Allogene Therapeutics in a report on Monday. William Blair initiated coverage on Allogene Therapeutics in a report on Wednesday. They issued an “outperform” rating for the company. Finally, Raymond James initiated coverage on Allogene Therapeutics in a report on Thursday. They issued an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Allogene Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $32.75.

Shares of Allogene Therapeutics stock traded up $0.05 during trading on Friday, reaching $26.58. The company’s stock had a trading volume of 4,193 shares, compared to its average volume of 364,316. Allogene Therapeutics Inc has a one year low of $21.67 and a one year high of $35.55. The stock has a market capitalization of $3.22 billion and a price-to-earnings ratio of -4.03.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.10). Equities analysts predict that Allogene Therapeutics Inc will post -2.06 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/4223962/1128584-shares-in-allogene-therapeutics-inc-allo-acquired-by-venbio-select-advisor-llc.html.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Institutional Ownership by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VikkyToken Achieves Market Cap of $28,771.00
VikkyToken Achieves Market Cap of $28,771.00
Head to Head Analysis: Key Energy Services  vs. RPC
Head to Head Analysis: Key Energy Services vs. RPC
Colu Local Network  Price Up 4.3% This Week
Colu Local Network Price Up 4.3% This Week
Gladstone Capital Co.  Expected to Announce Earnings of $0.21 Per Share
Gladstone Capital Co. Expected to Announce Earnings of $0.21 Per Share
Bitcoin Gold Reaches Market Capitalization of $392.92 Million
Bitcoin Gold Reaches Market Capitalization of $392.92 Million
Quanta Services Inc  Receives $42.80 Average PT from Brokerages
Quanta Services Inc Receives $42.80 Average PT from Brokerages


© 2006-2019 Ticker Report